Heparin-induced thrombocytopenia (HIT) after cardiac surgery presents a diagnostic problem: platelet counts commonly fall after cardiopulmonary bypass, and antibodies against platelet factor 4 (PF4)/heparin are much more frequent than clinically important HIT. Engelman, Cuker, and Chatterjee explain how the 2026 American Association for Thoracic Surgery (AATS) Expert Consensus Document adapts assessment and anticoagulation to this setting. Their article is an expert commentary on the consensus, rather than a new clinical trial.
Why the Postoperative Platelet Pattern Matters
The authors describe a typical platelet decline of 40% to 50% after bypass, with the lowest count on postoperative days two to three and recovery between days five and seven. This early fall can reflect the operation and extracorporeal circulation rather than an immune reaction to heparin. A second decline after initial recovery, or new thrombosis, changes the clinical picture and warrants reassessment.
Approximately half of patients develop anti-PF4/heparin antibodies after bypass, whereas reported clinical HIT incidence is only 0.5% to 3%. An immunoassay detects antibody binding; a functional assay assesses whether antibodies activate platelets. These tests answer different questions, so a positive antibody screen alone should not be equated with confirmed HIT.
Adapting HIT Testing After Cardiac Surgery
The first four postoperative days
As summarized in the commentary, AATS Statement 2.1 advises against using the 4Ts score to guide HIT testing during the first four days after cardiac surgery. Bypass-related platelet consumption and recent heparin exposure can inflate the score. Statement 2.2 identifies an important early testing scenario: preoperative unfractionated heparin exposure within the preceding five to ten days together with new thrombosis. This timing-specific approach does not mean that early thrombosis or other strong evidence of HIT should be ignored.
Interpreting antibody strength
The authors discuss an ELISA optical density (OD) of 1.0 as a threshold for treatment action in the cardiac surgical framework, rather than treating every result at the commonly reported positive cutoff of 0.4 as equally concerning. In a supporting observational cohort, the positive predictive value for platelet-activating antibodies increased from approximately 13% to 42% when the threshold rose from 0.4 to 1.0, without loss of sensitivity in that cohort. The threshold has not been prospectively validated in a dedicated cardiac surgical population.
OD is an ELISA measurement and should not be substituted for the units used by rapid immunoassays. The commentary separately reports a rapid-assay threshold above 1.0 U/mL in Statement 2.11. Assay interpretation must follow the specific laboratory method and the complete clinical assessment. The consensus also recommends functional confirmation of a positive immunoassay.
Balancing Thrombosis and Postoperative Bleeding
Starting a nonheparin anticoagulant can be lifesaving when HIT is likely, but it also exposes fresh surgical sites to bleeding. The commentary highlights Statement 2.7: in a patient with an intermediate 4Ts probability, no thrombosis, and an immunoassay pending, postponing empiric nonheparin anticoagulation until the result is available may be reasonable. The authors emphasize that this is an individualized physician decision, with documented bleeding risk, thrombosis assessment, current anticoagulation, and expected laboratory turnaround.
This recommendation is not a universal instruction to withhold anticoagulation. The patient’s probability of HIT, other reasons for anticoagulation, clinical stability, and access to rapid testing remain central. High clinical probability and stronger assay results require a different response under the full consensus pathway.
Implications for ECMO and Temporary Mechanical Support
The AATS framework includes postcardiotomy ECMO and temporary mechanical circulatory support, settings in which platelet counts can be difficult to interpret. The commentary reports that the 4Ts score should not guide HIT testing in postcardiotomy ECMO. It also describes direct thrombin inhibitor anticoagulation as a reasonable option in this population and summarizes the recommendation to discontinue all heparin and change to a direct thrombin inhibitor when HIT is suspected on ECMO.
For postcardiotomy microaxial flow pump support with concern for HIT, the authors describe a preference for a sodium bicarbonate-based purge over a heparin-based purge. Purge management and systemic anticoagulation are separate parts of the support plan and require coordination among the treating team, pharmacy, and perfusion staff. The commentary does not establish a universal drug dose or monitoring target for these devices.
Planning Surgery in Patients With Previous HIT
The authors describe preoperative immunoassay testing for patients with a history of HIT and delaying nonemergency surgery in confirmed HIT until a functional assay becomes negative. When HIT has resolved and the functional assay is negative, intraoperative unfractionated heparin may be appropriate even if the immunoassay remains positive, according to the consensus summarized in the paper.
That permission is limited to the intraoperative setting. It does not automatically extend to postoperative heparin exposure. The commentary emphasizes a nonheparin postoperative anticoagulation or prophylaxis plan when indicated, along with platelet monitoring because delayed HIT can follow even a single intraoperative exposure. Surgery that cannot wait while functional testing remains positive requires a specialist plan; evidence for adjunctive immunoglobulin or plasma exchange is limited.
Practical Relevance for Perfusion Teams
The central operational lesson is to connect platelet trends, heparin exposure, assay interpretation, and the anticoagulation plan before bypass or prolonged extracorporeal support. Perfusion teams need a clearly communicated strategy for the circuit, anticoagulant, monitoring method, and any mechanical support purge solution. A historic HIT label should prompt review of the documented diagnosis and current testing rather than an automatic assumption about the safest bypass strategy.
The commentary also identifies laboratory access as a system issue. It describes a consensus expectation for immunoassay testing seven days a week with results within 24 hours, while recognizing that functional assays often require referral testing. Knowing the actual local turnaround helps clinicians make and document interim treatment decisions.
Evidence Limitations and Disclosures
This paper interprets expert consensus supported largely by observational evidence and expert opinion. It does not provide a prospective comparison showing that the adapted pathway improves survival, reduces bleeding, or prevents thrombosis. Important gaps include validation of a bypass-specific probability score, prospective testing of the OD threshold, and stronger evidence for emergency surgery strategies. Its discussion centers on open cardiac surgery with bypass and postcardiotomy support; it should not be generalized automatically to transcatheter procedures or every ECMO population.
Engelman reports relationships with multiple device and pharmaceutical companies; Cuker reports consulting, authorship royalties, and institutional research support; Chatterjee reports no conflicts. The authors disclose using an AI tool for reference formatting and language editing, with author review and responsibility for the final work.
Original Article
Engelman DT, Cuker A, Chatterjee S. From general guidance to surgical reality: Adapting the heparin-induced thrombocytopenia algorithm for cardiac surgery. JTCVS Open. 2026;33:101976. doi:10.1016/j.xjon.2026.101976.
This independently written educational summary accompanies the unchanged source PDF, published under CC BY-NC-ND 4.0. Clinical statements above summarize the authors’ interpretation; the complete AATS consensus and local multidisciplinary protocols provide the full recommendations. The cover is an AI-generated editorial illustration.
